Short Interest in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Declines By 38.6%

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) saw a large decrease in short interest in May. As of May 15th, there was short interest totaling 6,068 shares, a decrease of 38.6% from the April 30th total of 9,883 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily trading volume, of 5,229 shares, the days-to-cover ratio is presently 1.2 days.

Molecular Partners Stock Down 3.1%

NASDAQ:MOLN traded down $0.12 during mid-day trading on Wednesday, hitting $3.80. 596 shares of the stock traded hands, compared to its average volume of 4,511. The business’s 50-day moving average price is $4.15 and its 200 day moving average price is $4.33. The company has a market cap of $153.43 million, a PE ratio of -1.96 and a beta of 1.07. Molecular Partners has a 12-month low of $3.41 and a 12-month high of $5.36.

Molecular Partners (NASDAQ:MOLN) last posted its earnings results on Monday, May 11th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.02). Analysts anticipate that Molecular Partners will post -1.4 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Molecular Partners

An institutional investor recently bought a new position in Molecular Partners stock. SmartHarvest Portfolios LLC purchased a new position in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 12,311 shares of the company’s stock, valued at approximately $54,000. Hedge funds and other institutional investors own 26.55% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently weighed in on MOLN. TD Cowen reiterated a “buy” rating on shares of Molecular Partners in a research note on Monday, March 16th. HC Wainwright reaffirmed a “buy” rating and issued a $13.00 price target on shares of Molecular Partners in a report on Wednesday, April 22nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Molecular Partners in a research note on Friday, April 10th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $8.38.

Molecular Partners Company Profile

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.